Trials / Completed
CompletedNCT01351805
Vitamin D and Fish Oil for Autoimmune Disease, Inflammation and Knee Pain
- Status
- Completed
- Phase
- N/A
- Study type
- Interventional
- Enrollment
- 25,871 (actual)
- Sponsor
- Brigham and Women's Hospital · Academic / Other
- Sex
- All
- Age
- 50 Years
- Healthy volunteers
- Accepted
Summary
The VITamin D and OmegA-3 TriaL (VITAL; NCT 01169259) is a randomized clinical trial in 25,871 U.S. men and women investigating whether taking daily dietary supplements of vitamin D3 (2000 IU) or omega-3 fatty acids (Omacor® fish oil, 1 gram) reduces the risk of developing cancer, heart disease, and stroke in people who do not have a prior history of these illnesses. This ancillary study is being conducted among VITAL participants and will examine whether vitamin D or fish oil have effects upon A) autoimmune disease incidence, B) biomarkers of systemic inflammation, and C) chronic knee pain. Blood samples at baseline and in follow-up will be collected in a randomly selected subcohort of 1500 individuals and analyzed for changes in biomarkers of systemic inflammation: C-reactive protein, interleukin-6, and tumor necrosis factor-receptor 2. Approximately 1300 individuals with chronic, frequent knee pain will be followed with annual questionnaires to evaluate the effects of the supplements on chronic knee pain.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Fish Oil | Subjects will receive marine omega-3 fatty acids (465 mg of eicosapentaenoic acid \[EPA\] and 375 mg of docosahexaenoic acid \[DHA\]). |
| DIETARY_SUPPLEMENT | Vitamin D | Subjects will receive vitamin D3 (cholecalciferol) 2000 IU a day. |
| OTHER | placebo pill | placebo |
Timeline
- Start date
- 2010-07-01
- Primary completion
- 2018-11-10
- Completion
- 2025-02-01
- First posted
- 2011-05-11
- Last updated
- 2025-12-03
- Results posted
- 2021-01-08
Locations
1 site across 1 country: United States
Source: ClinicalTrials.gov record NCT01351805. Inclusion in this directory is not an endorsement.